Alzheimer's disease and language impairments: social intervention and medical treatment

Blanka Klimova, Petra Maresova, Martin Valis, Jakub Hort, Kamil Kuca, Blanka Klimova, Petra Maresova, Martin Valis, Jakub Hort, Kamil Kuca

Abstract

Communication is very important for people to be successfully integrated into social environment and make and maintain relationship. Particularly, language difficulties lead to social exclusion of the people affected with Alzheimer's disease (AD) and contribute to a significant decrease in the quality of their life and also have a big impact on their family members who in most cases become their caregivers who need to communicate with their loved ones in order to meet their needs. Therefore, the goal of this study is to describe language impairments in the individual phases of AD and discuss their improvement with respect to AD on the basis of literature review. The authors of this article use traditional research methods in order to achieve the goal set mentioned earlier. First, a method of literature review of available sources describing language impairments in the individual phases of AD is exploited. Second, to show how informal caregivers and relevant drugs can successfully intervene in the improvement of these language impairments, a method of comparison of different research studies exploring such social intervention and medical treatment is used.

Keywords: Alzheimer’s disease; caregivers; clinical drugs; language impairments; social intervention; strategies.

Figures

Figure 1
Figure 1
Exploration of research studies.

References

    1. OECD Database Data: Population Development, Historical Data and Forecast. 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: .
    1. WHO International Classification of Diseases (ICD) 1994. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from:
    1. Stages of Alzheimer’s. Alzheimer’s Association 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: .
    1. Klímová B, Marešová P, Kuča K. Assistive technologies for language disorders in dementia [in review]
    1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292.
    1. Alzheimer’s Association Alzheimer’s Disease Facts and Figures. Alzheimer’s and Dementia. 2012. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: .
    1. Website of Charles F and Joanne Knight Alzheimer’s Disease Research Center (Knight ADRC) Washington University School of Medicine in St Louis; Missouri, USA: 2003. [Accessed April 20, 2015]. Dementia of the Alzheimer’s Type – Description of Stages. [cited June 9, 2015]. Available from: .
    1. National Institute on Aging . Alzheimer’s Disease. Unraveling 2 the Mystery; US: 2012. [Accessed April 20, 2015]. [cited Jun 9, 2015]. Available from: .
    1. Frederiks C, Hofmann MT, Reichard T. Advances in diagnosis and treatment of Alzheimer’s disease. Hosp Physician. 2002;5:47–54.
    1. Macoir J, Laforce R, Jr, Monetta L, Wilson M. Language deficits in major forms of dementia and primary progressive aphasias: an update according to new diagnostic criteria. Geriatr Psychol Neuropsychiatr Vieil. 2014;12(2):199–208.
    1. Shivanand P. Review on Alzheimer’s disease: its cause, symptoms, and treatment at worldwide. Int J Appl Biol Pharm Technol. 2009;1(1):112–120.
    1. Eliopoulos C, Carson VB, Varcarolis E. Evolve Resources for Varcarolis’ Foundations of Psychiatric Mental Health Nursing. St Louis, MO: Saunders Elsevier; 2006. Cognitive disorders.
    1. Pekkala S. Semantic Fluency in Mild and Moderate Alzheimer’s Disease. Helsinki: Hakapaino Oy; 2004.
    1. Orange JB, Colton-Hudson A. Enhancing communication in dementia of the Alzheimer’s type. Top Geriatr Rehabil. 1998;14(2):56–75.
    1. Savundranayagam ME, Ryan EB, Anas AP, Orange JB. Communication and dementia: staff perceptions of conversational strategies. Clin Gerontol. 2007;31(2):47–63.
    1. Ferris SH, Farlow M. Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging. 2013;8:1007–1014.
    1. Maresova P, Klimova B, Kuca K. Alzheimer’s disease: cost cuts call for novel drugs development and national strategy. Ceska A Slovenska Farmacie. 2015;64:25–30.
    1. EC . European Initiative on Alzheimer’s Disease and Other Dementias. Brussels: 2009. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: .
    1. Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol B Psychol Sci Soc Sci. 2005;60(1):S48–S55.
    1. Ripich DN. Functional communication with AD patients: a caregiver training program. Alzheimer Dis Assoc Disord. 1994;8(3):95–109.
    1. Manenti R, Repetto C, Bentrovato S, Marcone A, Bates E, Cappa SF. The effects of ageing and Alzheimer’s disease on semantic and gender priming. Brain. 2004;127(10):2299–2306.
    1. Tang-Wai DF, Graham NL. Assessment of language function in dementia. Geriatr Aging. 2008;11:103–110.
    1. Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9-year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005;128:1093–1101.
    1. Laws KR, Duncan A, Gale TM. “Normal’ semantic–phonemic fluency discrepancy in Alzheimer’s disease? A meta-analytic study. Cortex. 2010;46:595–601.
    1. Stern Y, Albert S, Tang MX, Tsai WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology. 1999;53:1942–1957.
    1. Fritsch T, McClendon MJ, Smyth KA, Ogrocki PK. Effects of educational attainment and occupational status on cognitive and functional decline in persons with Alzheimer-type dementia. Int J Geriatr Psychiatry. 2002;1:347–363.
    1. Capitani E, Laiacona M, Basso A. Phonetically cued word-fluency, gender differences and aging: a reappraisal. Cortex. 1998;34:779–783.
    1. Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010;24(1):90–95.
    1. DementiaGuide 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from:
    1. Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13(6):759–774.
    1. Nepovimova E, Uliassi E, Korabecny J, et al. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J Med Chem. 2014;57(20):8576–8589.
    1. Hilari K, Needle JJ, Harrison KL. What are the important factors in health-related quality of life for people with aphasia? A systematic review. Arch Phys Med Rehabil. 2012;93(suppl 1):86–95.
    1. Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement. 2009;5:369–374.
    1. Winblad B, Kilander L, Eriksson S, et al. Severe Alzheimer’s Disease Study Group Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057–1065.
    1. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459–469.
    1. Cummings J, Jones R, Wilkinson D, et al. Effect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysis. J Alzheimers Dis. 2010;21(3):843–851.
    1. Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25(11):2577–2587.
    1. Schwam E, Xu Y. Cognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe disease. Dement Geriatr Cogn Disord. 2010;29(4):309–316.
    1. Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer’s disease. Alzheimers Res Ther. 2011;3(3):22.
    1. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010;25(4):347–352.
    1. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010;25(8):627–633.
    1. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39.
    1. Clare L, Woods R. Cognitive rehabilitation in dementia. Neuropsychol Rehabil. 2001;11:193–517.
    1. Zientz J, Rackley A, Chapman SB, et al. Evidence-based practice recommendations for dementia: educating caregivers on Alzheimer’s disease and training communication strategies. J Med Speech Lang Pathol. 2007;15(1):liii–lxiv.
    1. Drug Treatment for Alzheimer’s Disease. 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: .
    1. Mayo Clinic Staff Alzheimer’s: Drugs Help Manage Symptoms. 2014. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: .
    1. Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer’s disease. Annu Rev Public Health. 2003;24:111–132.
    1. Kivipelto M, Solomon A. Alzheimer’s disease – the ways of prevention. J Nutr Health Aging. 2007;12:89–94.
    1. Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer’s disease. J Alzheimers Dis. 2010;20:777–783.
    1. Rovio S, Kåreholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol. 2005;4:705–711.
    1. Joe Verghese MD, Richard B, Lipton MD. Leisure Activities and the risk of dementia in the elderly. N Engl J Med. 2003;348:2508–2516.
    1. Craik FIM, Bialystock E, Freedman M. Delaying the onset of Alzheimer’s disease. Bilingualism as a form of cognitive reserve. Neurology. 2010;75(19):1726–1729.
    1. Bialystok E, Craik FIM, Luk G. Bilingualism: consequences for mind and brain. Trends Cogn Sci. 2012;16(4):240–250.
    1. Bialystok E, Craik FIM, Freedman M. Bilingualism as a protection against the onset of symptoms of dementia. Neuropsychologia. 2007;45:459–464.
    1. Soares FC, de Oliveira TC, de Macedo LD, et al. CANTAB object recognition and language tests to detect aging cognitive decline: an exploratory comparative study. Clin Interv Aging. 2015;10:37–48.
    1. Vestal L, Smith-Olinde L, Hicks G, Hutton T, Hart J., Jr Efficacy of language assessment in Alzheimer’s disease: comparing in-person examination and telemedicine. Clin Interv Aging. 2006;1(4):467–471.
    1. Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease – a simulation study. Curr Alzheimer Res. 2013;10:207–216.
    1. Soukup O, Jun D, Zdarova-Karasova J, et al. A resurrection of 7-MEOTA: a comparison with tacrine. Curr Alzheimer Res. 2013;10(8):893–906.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться